Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Expected to Rise, Maxim Group Analyst Says

Zevra Therapeutics (NASDAQ:ZVRA) had its price target upped by equities research analysts at Maxim Group from $25.00 to $35.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Maxim Group’s target price suggests a potential upside of 156.49% from the stock’s previous close.

A number of other brokerages have also weighed in on ZVRA. Citizens Jmp raised their price target on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a “market outperform” rating in a research note on Tuesday. HC Wainwright restated a “buy” rating on shares of Zevra Therapeutics in a report on Tuesday. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research report on Tuesday. Wall Street Zen lowered shares of Zevra Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Guggenheim raised their price target on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday. Eight analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Zevra Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $29.29.

Zevra Therapeutics Stock Performance

Shares of NASDAQ ZVRA traded down $0.01 during mid-day trading on Wednesday, hitting $13.65. The stock had a trading volume of 2,011,065 shares, compared to its average volume of 1,287,749. The firm has a market cap of $806.75 million, a PE ratio of 6.87 and a beta of 0.91. The company has a 50 day moving average of $10.46 and a two-hundred day moving average of $9.42. Zevra Therapeutics has a twelve month low of $7.16 and a twelve month high of $14.27.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.18 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.12. The company had revenue of $36.22 million for the quarter, compared to the consensus estimate of $31.96 million. Zevra Therapeutics had a return on equity of 51.49% and a net margin of 101.58%. Equities research analysts predict that Zevra Therapeutics will post 0.56 EPS for the current fiscal year.

Institutional Investors Weigh In On Zevra Therapeutics

Several hedge funds have recently made changes to their positions in the business. ProShare Advisors LLC raised its stake in shares of Zevra Therapeutics by 12.3% during the fourth quarter. ProShare Advisors LLC now owns 12,669 shares of the company’s stock valued at $114,000 after purchasing an additional 1,390 shares during the period. The Manufacturers Life Insurance Company increased its stake in Zevra Therapeutics by 9.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,294 shares of the company’s stock worth $179,000 after buying an additional 1,750 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Zevra Therapeutics by 6.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock worth $238,000 after buying an additional 1,812 shares in the last quarter. Deutsche Bank AG boosted its position in Zevra Therapeutics by 4.4% in the 4th quarter. Deutsche Bank AG now owns 45,939 shares of the company’s stock valued at $412,000 after buying an additional 1,936 shares during the last quarter. Finally, MetLife Investment Management LLC grew its stake in shares of Zevra Therapeutics by 10.5% during the fourth quarter. MetLife Investment Management LLC now owns 27,867 shares of the company’s stock valued at $250,000 after acquiring an additional 2,653 shares in the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.